Hedging Whale Executes Time-based Order to Sell 63,000 HYPE Spot, Holding $25 Million Short Position in Contract Unwound
BlockBeats News, April 16th, according to Hyperinsight monitoring, the hedge whale "HYPE Maximum Short" on Hyperliquid has started to sell off its spot position today. The address has densely placed 9 sell orders for approximately $28 million worth of HYPE spot held, totaling 63,000 HYPE through a TWAP (Time-Weighted Average Price) strategy, with a value of around $2.86 million. Currently, over half of the orders have been executed.
At the same time, the whale still holds a 5x leveraged HYPE short position worth $25 million, with an average price of $38.93, currently experiencing a floating loss of $3.54 million (-70%), making it the largest short holder of HYPE on the platform.
Usually, the strategy of hedging spot positions with short positions often involves simultaneously closing out some short positions to lock in profits when selling spot. However, the whale has not yet made any adjustments to the HYPE short position, perhaps intending to bet on a short-term price reversal of HYPE to offset the unrealized losses in the short position.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Iranian President will head to New York for UN meeting
"Big Short" Burry opens a position in QXO (QXO.US), betting on building products integration and undervaluation; stock price rises over 7%
Investor Michael Burry disclosed that he has purchased common and preferred shares of QXO (QXO.US), a building products company, citing its integration strategy and the currently depressed stock price. The stock surged 7.2% on Monday.
700,000 new elderly patients join, Eli Lilly (LLY.US) dominates 70%: The first Medicare weight loss drug coverage report released
Dave Ricks, CEO of Eli Lilly (LLY.US), said in an interview on Monday that since Medicare began coverage for obesity drugs in July, 700,000 new elderly patients have started using GLP-1 medications.
Market Is Primed for a ‘Face Ripper' Rally Thanks to Four Ingredients Says Tom Lee
